Lexicon Pharmaceuticals (LXRX) Cash & Equivalents (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has reported Cash & Equivalents for 17 consecutive years, with $38.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents fell 39.43% year-over-year to $38.1 million; the TTM figure through Mar 2026 stood at $38.1 million (down 39.43% YoY), while the FY2025 annual figure was $34.3 million, down 48.5% from the prior year.
• Cash & Equivalents advanced to $38.1 million in Q1 2026 per LXRX's latest filing, from $34.3 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $102.3 million in Q2 2023 and bottomed at $18.8 million in Q3 2022.
• Historically, Cash & Equivalents has averaged $44.6 million across 5 years, with a median of $35.6 million in 2024.
• Annual changes were most pronounced in 2022 — Cash & Equivalents slumped 79.55% — and 2023, when it surged 376.79%.
• Lexicon Pharmaceuticals' Cash & Equivalents stood at $46.3 million in 2022, then sank by 51.53% to $22.5 million in 2023, then surged by 196.71% to $66.7 million in 2024, then tumbled by 48.5% to $34.3 million in 2025, then grew by 10.96% to $38.1 million in 2026.
• Business Quant data shows LXRX's Cash & Equivalents at $38.1 million in Q1 2026, $34.3 million in Q4 2025, and $49.7 million in Q3 2025.